Price movement over the last 24 hours
ADMA Biologics Inc vs ProShares Ultra Semiconductors — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while ProShares Ultra Semiconductors trades at $89.34. The key difference: ProShares Ultra Semiconductors is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | USD | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $20.38 | $113.53 |
52-Week Low | $7.60 | $37.63 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
USD stock trades at $90.36, up 3.26% with a bearish technical signal from moving averages. The company announced a $0.14 dividend payable June 30, 2026. Recent news highlights institutional interest with JPMorgan Chase increasing its stake by 325% in Q3 2026. Technical indicators show neutral oscillators but bearish momentum with key support at $85 and resistance at $93.
The stock faces headwinds from bearish technical momentum despite recent price gains. Institutional accumulation and dividend payments provide support, but the overall technical picture suggests caution. Semiconductor sector volatility remains a key risk factor for this leveraged ETF.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →